Arkolith/Insider Trading/SKYE/Form 4/A

Arsenault Kaitlyn

Chief Financial OfficerSkye Bioscience, Inc. (SKYE) · full profile →Form 4/A · filed Feb 28, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$216K
Net Open-Market Flow
-$216K
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Nov 18, 2024Sell(S)43K$4.99$215K168K
Nov 15, 2024Sell(S)190$5.55$1K211K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4/A filing (accession 0001516551-25-000022) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4/A XML